AU7322398A - Methods and compositions for the detection of soluble beta-amyloid peptide - Google Patents

Methods and compositions for the detection of soluble beta-amyloid peptide

Info

Publication number
AU7322398A
AU7322398A AU73223/98A AU7322398A AU7322398A AU 7322398 A AU7322398 A AU 7322398A AU 73223/98 A AU73223/98 A AU 73223/98A AU 7322398 A AU7322398 A AU 7322398A AU 7322398 A AU7322398 A AU 7322398A
Authority
AU
Australia
Prior art keywords
compositions
detection
methods
amyloid peptide
soluble beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU73223/98A
Other versions
AU722044C (en
AU722044B2 (en
Inventor
Dale B. Schenk
Michael G. Schlossmacher
Dennis J. Selkoe
Peter A Seubert
Carmen Vigo-Pelfrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Elan Pharmaceuticals LLC
Eli Lilly and Co
Original Assignee
Brigham and Womens Hospital Inc
Elan Pharmaceuticals LLC
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU48444/93A external-priority patent/AU687747C/en
Application filed by Brigham and Womens Hospital Inc, Elan Pharmaceuticals LLC, Eli Lilly and Co filed Critical Brigham and Womens Hospital Inc
Priority to AU73223/98A priority Critical patent/AU722044C/en
Publication of AU7322398A publication Critical patent/AU7322398A/en
Application granted granted Critical
Publication of AU722044B2 publication Critical patent/AU722044B2/en
Publication of AU722044C publication Critical patent/AU722044C/en
Assigned to BRIGHAM AND WOMEN'S HOSPITAL, ELI LILLY AND COMPANY, ELAN PHARMACEUTICALS, INC. reassignment BRIGHAM AND WOMEN'S HOSPITAL Alteration of Name(s) in Register under S187 Assignors: SCHENK, DALE B., SCHLOSSMACHER, MICHAEL G., SELKOE, DENNIS J., SEUBERT, PETER A, VIGO-PELFREY, CARMEN
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU73223/98A 1992-10-26 1998-06-26 Methods and compositions for the detection of soluble beta-amyloid peptide Expired AU722044C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73223/98A AU722044C (en) 1992-10-26 1998-06-26 Methods and compositions for the detection of soluble beta-amyloid peptide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US965972 1992-10-26
AU48444/93A AU687747C (en) 1992-10-26 1993-09-01 Methods and compositions for the detection of soluble beta-amyloid peptide
AU73223/98A AU722044C (en) 1992-10-26 1998-06-26 Methods and compositions for the detection of soluble beta-amyloid peptide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU48444/93A Division AU687747C (en) 1992-10-26 1993-09-01 Methods and compositions for the detection of soluble beta-amyloid peptide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU66628/00A Division AU6662800A (en) 1992-10-26 2000-10-19 Methods and compositions for the detection of soluble beta-amyloid peptide
AU2004203875A Division AU2004203875A1 (en) 1992-10-26 2004-08-13 Methods and compositions for the detection of soluble beta-amyloid peptide

Publications (3)

Publication Number Publication Date
AU7322398A true AU7322398A (en) 1998-11-26
AU722044B2 AU722044B2 (en) 2000-07-20
AU722044C AU722044C (en) 2001-07-26

Family

ID=3735155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73223/98A Expired AU722044C (en) 1992-10-26 1998-06-26 Methods and compositions for the detection of soluble beta-amyloid peptide

Country Status (1)

Country Link
AU (1) AU722044C (en)

Also Published As

Publication number Publication date
AU722044C (en) 2001-07-26
AU722044B2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
AU3691793A (en) Gas well treatment compositions and methods
AU7564694A (en) Erection-inducing methods and compositions
AU7323294A (en) Perfluoroelastomeric compositions and methods
AU4781693A (en) Camptothecin analogues and methods of preparation thereof
IL105806A0 (en) Aminoquinoline derivatives and pharmaceutical compositions containing the same
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
AU3249793A (en) Compositions and methods for modulating beta -amyloid
AU2157192A (en) 4-aminoquinolines and pharmaceutical compositions thereof
AU1437895A (en) Methods and compositions for the detection of colon cancers
AU6883791A (en) Anti-thrombotic peptides and pseudopeptides
AU6959694A (en) Antineoplastic compositions and methods of use
ZA9410056B (en) Indoline derivatives method of preparation and use
AU3461095A (en) Compositions and methods for delivery of polypeptides
AU4496697A (en) Materials and methods for detection of (oxalobacter)
AU651992B2 (en) Polyethylene terephthalate compositions and methods of using thereof
AU7275894A (en) Imidazolylalkylamine derivative and pharmaceutical composition thereof
AU7008394A (en) Methods and compositions for detection of (salmonella)
AU6308494A (en) Process for the preparation of microballs and microballs thus obtained
AU6774694A (en) Taste-masking pharmaceutical compositions and methods for making the same
AU5847694A (en) Chlorofluoroether compositions and preparation thereof
AU4505996A (en) 7-vinylidene cephalosporins and methods of using the same
AU4573793A (en) N-cycloalkylpiperazine derivatives, methods of obtaining them and pharmaceutical compositions containing them
AU1225492A (en) Process for the detection and localization of cancer
AU5686794A (en) (2-quinoxalinyloxy)phenoxypropanoic acids and related derivatives as anticancer agents
AU6575594A (en) Point of incidence detection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20001122

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20010104

PC Assignment registered

Owner name: ELAN PHARMACEUTICALS, INC., BRIGHAM AND WOMEN S HO

Free format text: FORMER OWNER WAS: DALE B. SCHENK, MICHAEL G SCHLOSSMACHER, DENNIS J. SELKOE, PETER A SEUBERT, CARMEN VIGO-PELFREY